Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period [Phase 3]

View source ↗

Summary

An update on a Phase 3 pediatric trial evaluating the efficacy and safety of mitapivat in children with pyruvate kinase deficiency who are not regularly transfu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Anemia
• Pyruvate Kinase Deficiency

Drugs mentioned

• Mitapivat (mitapivat)
• Pyrukynd (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING